Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

InMed Pharmaceuticals Inc. (INM) vs cbdMD, Inc. (YCBD)

InMed Pharmaceuticals Inc. and cbdMD, Inc. are both Drug Manufacturers Specialty & Generic companies. InMed Pharmaceuticals Inc. is the larger, with a market value of $7.7M against $4.8M — 1.6× the size. InMed Pharmaceuticals Inc. has negative trailing earnings, so its P/E is not meaningful; cbdMD, Inc. trades at 55.3×. InMed Pharmaceuticals Inc. grew revenue faster over the last twelve months: 19.4% against 10.0%. InMed Pharmaceuticals Inc. has the higher net margin (0.00% vs −14.7%) and the higher return on invested capital (0.00% vs −29.8%). Across the 16 metrics below, cbdMD, Inc. leads on 10 and InMed Pharmaceuticals Inc. on 6.

Valuation

Metric INM YCBD Drug Manufacturers Specialty & Generic median
P/E n/m 55.29 20.14
P/S 1.00 0.24 2.25
P/B 5.35 0.61 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 0.65 0.26 2.56
Earnings yield (218.43%) 1.81% (2.99%)
Free cash flow yield (151.13%) (49.69%) 0.00%

Profitability

Metric INM YCBD Drug Manufacturers Specialty & Generic median
Gross margin 26.27% 57.68% 53.94%
Operating margin 0.00% (13.87%) 0.00%
Net margin 0.00% (14.71%) 0.00%
Free cash flow margin 0.00% (11.51%) 0.00%
Return on equity (179.09%) (43.01%) (0.40%)
Return on assets (139.63%) (26.73%) (3.32%)
Return on invested capital 0.00% (29.78%) 0.00%

Growth

Metric INM YCBD Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 19.38% 10.01% 10.01%
EPS growth (last fiscal year) 62.68% 92.39% —
Revenue growth, 5-year CAGR — (14.45%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INM YCBD Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.05
Current ratio 1.37 2.50 2.31
Net debt to EBITDA 0.20 6.17 0.85

Dividend

Metric INM YCBD Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric INM YCBD Drug Manufacturers Specialty & Generic median
Market cap 7.69m 4.76m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack